Compare 10X Genomics Inc (TXG) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? 10X Genomics Inc trades at $57.12 (market cap $7.61B), while Direxion Daily FTSE China Bull 3x Shares trades at $29.24. The key difference: 10X Genomics Inc is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| TXG | YINN | |
|---|---|---|
Market Cap | $7.61B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $58.57 | $56.62 |
52-Week Low | $11.34 | $21.45 |
Enterprise Value | $7.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
YINN, a leveraged ETF tracking Chinese equities, trades at $29.20, down 9.6% in 24 hours amid bearish technical signals. Key support lies at $29, with resistance at $30–31. The fund's structure amplifies volatility, and financial ratios are unavailable due to its ETF nature. Recent news highlights China's AI investments and trade resilience, but geopolitical tensions and regulatory scrutiny persist.
Outlook remains cautious due to leverage risks and China's economic uncertainties. Opportunities exist if Hang Seng rebounds, but investors face elevated volatility from US-China frictions and ETF decay. Risks outweigh near-term catalysts, warranting careful position sizing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
